Contact
searchSearch
HMP Global
Login

Colorectal Cancer Specialty Channel

Colorectal Cancer
Specialty Channel
News
Capecitabine Monotherapy for Elderly Patients With MRD-Negative High-Risk Colorectal Cancer
12/02/2025
Stephanie Holland
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy...
12/02/2025
Oncology
News
Low-Dose Aspirin Significantly Reduces Recurrence in PI3K-Altered Localized Colorectal Cancer
11/24/2025
Stephanie Holland
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the...
11/24/2025
Oncology
News
Neoadjuvant FOLFOXIRI Demonstrates Favorable Safety and Deliverability in High-Risk Locally Advanced Colon Cancer
11/19/2025
Stephanie Holland
According to results from a prospective phase 2 trial, neoadjuvant FOLFOXIRI demonstrated favorable safety, deliverability, and encouraging clinical activity in patients with high-risk locally advanced colon cancer.
According to results from a prospective phase 2 trial, neoadjuvant FOLFOXIRI demonstrated favorable safety, deliverability, and encouraging clinical activity in patients with high-risk locally advanced colon cancer.
According to results from a...
11/19/2025
Oncology
News
Adjuvant Chemotherapy Significantly Improved Survival Benefit Among Elderly Patients With Stage 3 Colon Cancer
10/06/2025
Stephanie Holland
According to results from a real-world, population-based study, adjuvant chemotherapy significantly improved survival benefit among patients ≥ 75 years of age with stage 3 colon cancer.
According to results from a real-world, population-based study, adjuvant chemotherapy significantly improved survival benefit among patients ≥ 75 years of age with stage 3 colon cancer.
According to results from a...
10/06/2025
Oncology
Quiz
Avelumab Following Long-Course Chemoradiotherapy for Patients With Locally Advanced, Resectable Colorectal Cancer
09/30/2025
In the phase 2 Ave-Rec trial researchers assessed avelumab after long-course chemoradiotherapy among patients with locally advanced, resectable colorectal cancer (CRC). Which of the following statements best summarizes the significance of...
In the phase 2 Ave-Rec trial researchers assessed avelumab after long-course chemoradiotherapy among patients with locally advanced, resectable colorectal cancer (CRC). Which of the following statements best summarizes the significance of...
In the phase 2 Ave-Rec trial...
09/30/2025
Oncology
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
Quiz
Atezolizumab Plus mFOLFOX for Patients With Mismatch Repair Deficient Colon Cancer
07/29/2025
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the...
07/29/2025
Oncology
Conference Coverage
Circulating Tumor DNA Methylation-Guided Postoperative Surveillance For Patients With Non-Metastatic Colorectal Cancer
07/08/2025
Allison Casey
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis...
07/08/2025
Oncology

News

News
Capecitabine Monotherapy for Elderly Patients With MRD-Negative High-Risk Colorectal Cancer
12/02/2025
Stephanie Holland
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy...
12/02/2025
Oncology
News
Low-Dose Aspirin Significantly Reduces Recurrence in PI3K-Altered Localized Colorectal Cancer
11/24/2025
Stephanie Holland
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the...
11/24/2025
Oncology
News
Neoadjuvant FOLFOXIRI Demonstrates Favorable Safety and Deliverability in High-Risk Locally Advanced Colon Cancer
11/19/2025
Stephanie Holland
According to results from a prospective phase 2 trial, neoadjuvant FOLFOXIRI demonstrated favorable safety, deliverability, and encouraging clinical activity in patients with high-risk locally advanced colon cancer.
According to results from a prospective phase 2 trial, neoadjuvant FOLFOXIRI demonstrated favorable safety, deliverability, and encouraging clinical activity in patients with high-risk locally advanced colon cancer.
According to results from a...
11/19/2025
Oncology
News
Adjuvant Chemotherapy Significantly Improved Survival Benefit Among Elderly Patients With Stage 3 Colon Cancer
10/06/2025
Stephanie Holland
According to results from a real-world, population-based study, adjuvant chemotherapy significantly improved survival benefit among patients ≥ 75 years of age with stage 3 colon cancer.
According to results from a real-world, population-based study, adjuvant chemotherapy significantly improved survival benefit among patients ≥ 75 years of age with stage 3 colon cancer.
According to results from a...
10/06/2025
Oncology
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
Conference Coverage
Circulating Tumor DNA Methylation-Guided Postoperative Surveillance For Patients With Non-Metastatic Colorectal Cancer
07/08/2025
Allison Casey
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis...
07/08/2025
Oncology
News
Lean Body Mass-Based Dose Adjustments Significantly Reduces the Rate of Oxaliplatin-Induced Peripheral Neurotoxicity in Colon Cancer
07/01/2025
Stephanie Holland
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX...
07/01/2025
Oncology

Interactive Features

Quiz
Avelumab Following Long-Course Chemoradiotherapy for Patients With Locally Advanced, Resectable Colorectal Cancer
09/30/2025
In the phase 2 Ave-Rec trial researchers assessed avelumab after long-course chemoradiotherapy among patients with locally advanced, resectable colorectal cancer (CRC). Which of the following statements best summarizes the significance of...
In the phase 2 Ave-Rec trial researchers assessed avelumab after long-course chemoradiotherapy among patients with locally advanced, resectable colorectal cancer (CRC). Which of the following statements best summarizes the significance of...
In the phase 2 Ave-Rec trial...
09/30/2025
Oncology
Quiz
Atezolizumab Plus mFOLFOX for Patients With Mismatch Repair Deficient Colon Cancer
07/29/2025
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the...
07/29/2025
Oncology
Quiz
Quiz: Incidence of Anal Cancer
05/18/2023
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has...
05/18/2023
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Plus CRT After FOLFOX Provide Benefit for LARC?
09/03/2021
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the...
09/03/2021
Oncology
Quiz
Quiz: Which Therapy Enhances Tumor Immunologic Response in LARC?
08/09/2021
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Does Coffee Consumption Yield Benefit in CRC?
04/05/2021
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds...
04/05/2021
Oncology
Test Your Knowledge
Quiz: What Are the 3 Current Modalities for Rectal Cancer?
03/24/2021
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3...
03/24/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology

Recent News

News
Capecitabine Monotherapy for Elderly Patients With MRD-Negative High-Risk Colorectal Cancer
12/02/2025
Stephanie Holland
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy...
12/02/2025
Oncology
News
Low-Dose Aspirin Significantly Reduces Recurrence in PI3K-Altered Localized Colorectal Cancer
11/24/2025
Stephanie Holland
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the...
11/24/2025
Oncology
News
Neoadjuvant FOLFOXIRI Demonstrates Favorable Safety and Deliverability in High-Risk Locally Advanced Colon Cancer
11/19/2025
Stephanie Holland
According to results from a prospective phase 2 trial, neoadjuvant FOLFOXIRI demonstrated favorable safety, deliverability, and encouraging clinical activity in patients with high-risk locally advanced colon cancer.
According to results from a prospective phase 2 trial, neoadjuvant FOLFOXIRI demonstrated favorable safety, deliverability, and encouraging clinical activity in patients with high-risk locally advanced colon cancer.
According to results from a...
11/19/2025
Oncology
News
Adjuvant Chemotherapy Significantly Improved Survival Benefit Among Elderly Patients With Stage 3 Colon Cancer
10/06/2025
Stephanie Holland
According to results from a real-world, population-based study, adjuvant chemotherapy significantly improved survival benefit among patients ≥ 75 years of age with stage 3 colon cancer.
According to results from a real-world, population-based study, adjuvant chemotherapy significantly improved survival benefit among patients ≥ 75 years of age with stage 3 colon cancer.
According to results from a...
10/06/2025
Oncology
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
News
Lean Body Mass-Based Dose Adjustments Significantly Reduces the Rate of Oxaliplatin-Induced Peripheral Neurotoxicity in Colon Cancer
07/01/2025
Stephanie Holland
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX...
07/01/2025
Oncology
Conference Coverage
Liquid Biopsy-Guided Anti-EGFR Retreatment Improves Survival and Response Rates in Metastatic Colorectal Cancer
06/01/2025
Emily Estrada
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial...
06/01/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use